news

Archive News

2016.11.11.

We have moved our archive new content here.

 

2015

BIO Europe conference Cologne, Germany

Pharmahungary Group will attend the BIO-Europe convention in Cologne, Germany between November 7-9. We are looking forward to meeting you there and discussing with you how we can collaborate in the further development of your projects with our innovative preclinical and clinical R&D services.

XXII. ISHR World Congress: Buenos Aires

Our Founder and CEO, Prof. Peter Ferdinandy, 2014 “highlycited” researcher is attending the XXII. International Society for Heart Research (ISHR) World Congress in Buenos Aires, Argentina.

We are looking forward to meeting you April 18-21, 2016 in South America!

Budapest Upgrade CRT

Pharmahungary Group, as clinical R&D service provider is coordinating an international Investigator Initiated Trial in cardio intervention indication with CRT-D medical device. As the CRO of the Budapest Upgrade CRT trial Pharmahungary is responsible for all European sites including CA/CEC submission and site management during the course of the trial. The trial is currently recruiting in 5 countries with 10 sites. For more information: https://clinicaltrials.gov/ct2/show/NCT02270840.

Conference of NIPH: Generation-strategy-change

Our Clinical Director attended the scientific conference organised by National Institute of Pharmacy and Nutrition (NIPH) titled „Generation-strategy-change” on December 14, 2015. The topics of the conference included recent changes in national and international legislation of medical devices and drugs, Horizon 2020 best practices and facilitated a better communication between the Hungarian Competent Authorities and the biotechnology industry.

The Hungarian Society for Experimental and Clinical Pharmacology has held its annual conference in Debrecen on the recent developments of changes in Hungarian and international legislation related to clinical pharmacology between December 3-5, 2015. Our CEO and Clinical Director as certified Clinical Pharmacologists attended the conference and participated in sections on approving clinical trials.

BIO-Europe 2015: partnering with Pharmahungary

Pharmahungary Group will attend the BIO-Europe convention in Munich, Germany between November 2-4. We are looking forward to discussing with you how we can further your development project with our innovative preclinical and clinical R&D services.

33rd Annual meeting of the European Section of ISHR

Meet Pharmahungary Group in Bordeaux, France between July 1-4 at the 33rd Annual meeting of the European Section of ISHR. We are looking forward to discussing potential collaboration opportunities with you!

ESC Congress 2015: London

The European Society of Cardiology Congress will take place in London, UK between August 29-September 2. Meet Pharmahungary Group there and discuss how you might benefit from our over 20 years of experience in drug development projects.

EuroMedTech 2015: meet us in Vienna!

On June 10-11, Pharmahungary will attend the premier European Medtech partnering event, the IN3 EuroMedTech convention in Vienna, Austria.
We are looking forward to meet you there and discussing how you might benefit from our innovative clinical R&D services.

2014

BIO Europe: meet us in Frankfurt!

The 20th BIO Europe convention will be held in Frankfurt, Germany between November 3-5, 2014. We are looking forward to schedule a one-on-one meeting with you to discuss collaboration opportunities.

1. Preclinical R&D services: focusing on cardiovascular (infarction, heart failure, stroke, sepsis, arrhythmias, etc) and metabolic diseases (diabetes, dyslipidemia, hyperlipidemia, atherosclerosis, obesity, uremia, etc) with strong scientific support

2. Clinical R&D services: focusing on Investigator Initiated Trials (IIT), medical devices, unique clinical studies including  that need sensitive patient population and thereby strong regulatory & scientific support

3. In-house R&D projects open for out-licensing and/or co-development

Founder and CEO: noticed as a “higlycited” researcher

Founder and CEO of Pharmahungary has been noticed as a “higlycited” researcher. Highly Cited Researchers 2014 represents some of world’s leading scientific minds. Over three thousand researchers in total of 21 research area earned the distinction by writing the greatest numbers of reports officially designated by Essential Science Indicators™ as Highly Cited Papers—ranking among the top 1% most cited for their subject field and year of publication, earning them the mark of exceptional impact.

For our selected publications click here and for a full list here.

BIO San Diego: meet us there!

Pharmahungary Group will exhibit at the BIO International Convention in San Diego, between June 24-26. We are looking forward to meeting you there and discussing collaboration opportunities.

1. Preclinical R&D services: focusing on cardiovascular (infarction, heart failure, stroke, sepsis, arrhythmias, etc) and metabolic diseases (diabetes, dyslipidemia, hyperlipidemia, atherosclerosis, obesity, uremia, etc) with strong scientific support

2. Clinical R&D services: focusing on unique clinical studies including medical devices that need sensitive patient population and thereby strong regulatory & scientific support

3. In-house R&D projects open for out-licensing and/or co-development

EuroMedtech 2014: meet us in Linz!

Pharmahungary Group will attend the 6th EuroMedtech International Partnering Conference in Linz, Austria on May 7-8. We are looking forward to meeting with you there and discussing possible collaboration opportunities, especially in our clinical R&D services:
medical device clinical trials / registry
-post market clinical follow up
investigator initiated research trials
– preparation of clinical evaluation report for CE mark
regulatory and ethics committee consulting
unique clinical trials

2013

Horizon 2020: calls for projects

The European Comission has presented the first calls for projects under Horizon 2020.

Pharmahungary Group as a Hungarian SME is ready to be your partner for Horizon 2020 projects with  our innovative preclinical and clinical R&D services.

Contact us today for further information on how Pharmahungary Group can assist you in your projects!

Interview with Founder and CEO

The Australian biotech company Cellmid has recently interviewed Pharmahungary Group Founder and CEO, Prof. Péter Ferdinandy in their newsletter. Pharmahungary Group has been involved in the research and development of midkine for years as a partner of Cellmid. In the interview Prof. Ferdinandy talks about the forthcoming Midkine Themed Issue of British Journal of Pharmacology.

BIO Europe 2013: Vienna

Pharmahungary Group will attend the 19th annual BIO Europe conference held in Vienna, Austria between November 4-6.

We invite you to meet with us their to learn more about our innovative preclinical and clinical R&D services and our in-house R&D projects that are open for out-licensing and/or co-development. Look for us in the partnering system!

For more information, please do not hesitate to contact us at businessdevelopment@pharmahungary.com.

ESC Congress 2013

The ESC Congress 2013 will be held in Amsterdam, The Netherlands between 31 August-4 September 2013. Pharmahungary Group is looking forward to meeting you there!

XXI ISHR World Congress

Pharmahungary Group will attend the XXI ISHR world congress between June 30-July 4, 2013 in San Diego, California. We are looking forward to meeting you there.

BIO Chicago 2013

Meet Pharmahungary Group in Chicago at the BIO International Convention  between 22-25 April 2013.

Our CEO and BDO is looking forward to meet with you during the conference to explore possible synergies between Your company and Pharmahungary Group. Look for us in the parntering system and in the exhibitor section at Booth 0601 as well!

EuroMedtech 2013

Dr. Eszter Fodor, Clinical and Marketing Director of Pharmahungary Group will attend this year’s EuroMedtech conference in Düsseldorf, Germany. Look for us in the partnering system and meet us on 7-8 of May 2013.

Polish-Hungarian Economic Forum

Peter Ferdinandy, founder and CEO of Pharmahungary, and Pawel Przewiezlikowski, president of Selvita, were panelists together with the President of Hungary, János Áder, and President of Poland Bronisław Komorowski at the Polish-Hungarian Economical Forum, Tarnów, Poland on March 23, the Polish-Hungarian friendship day. The panelists discussed the success of the knowledge-based economy and the tasks to be accomplished to further facilitate this sector, including the importance of the flexible collaboration between universities and small-medium enterprises.

BioForum 2013 Budapest

Pharmahungary Group will attend the BioForum, the biggest biotech & pharma event in Central Europe on the 22nd and 23rd of May in Budapest, Hungary.

We are looking forward to meeting you there!

2012

Bio-Europe Hamburg 2012

Pharmahungary Group will be attending the 2012 Bio-Europe Conference as is tradition. Meet us in Hamburg, Germany from the 12th of November until the 14th 2012

BIO Boston 2012

You can meet Pharmahungary Group at the next Bio Convention conference in Boston, MA, USA from the 18th of June to the 21st 2012. You can find us in the partnering system as well.

Upgraded Infarctsize system

2012 Jan: Pharmahungary concluded the development of an upgraded version of its proprietary “infarctsize” system to measure the extent of myocardial infarction in preclinical models. The system consists of a high-throughput, precision slicing hardware as well as image analyzer & documentation software designed for the special needs for fast and reproducible measurement and documentation of infarct size. Infarctsize is a trademark of Pharmahungary, see www.infarctsize.com.

Tamiflu pharmacokinetic clinical study

2012 Jan: Pharmahungary has got regulatory approval for the extension of a Tamiflu pharmacokinetic clinical study (ClinicalTrials.gov Identifier: NCT01130636). The study is sponsored by Pharmahungary and supported by F. Hoffman-La Roche. Patient recruitment is currently ongoing in the endemic season in Hungary.

2011

MMP PCT patent application

2011 Dec: MMPharma consortium submitted PCT patent application as a conclusion of a three-year research project. The primary focus of the research was MMP-2 inhibition by small molecules for anti-ischemic and myocardial infarction applications. However, the consortium successfully developed selective inhibitors for not only MMP-2, but MMP-9 and 13 as well, useful targets for treatment of various pathologies. The patent is owned by 3 private Hungarian companies of the MMPharma consortium: Pharmahungary (leader of the consortium), InFarmatik (a drug discovery company), and TargetEx (recombinant protein production and assay development CRO). Since the consortium is actively working to collect additional biological data, further information is available under CDA. For further non-confidential details, see www.MMPharma.com.

Pharmahungary submitted patent application

Pharmahungary submitted patent application on cytoprotective microRNAs in Q3, 2011. The patent portfolio of Pharmahungary includes 4 technologies, for further details, see In-house R&D projects.

2010

Pharmahungary and Cellmid sign collaboration

2010 March 4, Press release: Pharmahungary and Cellmid (Sydney, Australia) sign collaboration and R&D agreements to develop midkine therapies for myocardial infarction.

Pharmahungary launches new services and products

– noninvasive ultrasound imaging of the heart in acute myocardial infacrtion as well as in acute and chronic heart failure models
– why spend time for in vivo or ex vivo experiments, buy rodent myocardial tissue obtained from custom design experimental protocols (e.g. ischemia/reperfusion, postconditioning, hyperlipidemia, etc.)
– myocardial infarction in large animal models
– uremia models (partial nephrectomy)

2008

Breaking news by Thomson Reuters

A recent publication of Pharmahungary (Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 59:418-458, 2007) has been selected by Essential Science Indicators as a Fast Breaking Paper in the field of Pharmacology & Toxicology.